Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Curevac N.V. (CVAC)

Curevac N.V. (CVAC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,502,641
  • Shares Outstanding, K 186,913
  • Annual Sales, $ 55,830 K
  • Annual Income, $ -147,500 K
  • 60-Month Beta N/A
  • Price/Sales 194.33
  • Price/Cash Flow N/A
  • Price/Book 15.55
Trade CVAC with:

Options Overview Details

View History
  • Implied Volatility 79.70%
  • Historical Volatility 59.01%
  • IV Percentile 17%
  • IV Rank 19.44%
  • IV High 131.97% on 05/06/21
  • IV Low 67.09% on 08/25/21
  • Put/Call Vol Ratio 0.57
  • Today's Volume 233
  • Volume Avg (30-Day) 544
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 9,674
  • Open Int (30-Day) 14,966

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.76
  • Number of Estimates 1
  • High Estimate -0.76
  • Low Estimate -0.76
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.06 +7.97%
on 09/20/21
73.00 -23.00%
on 08/30/21
-16.04 (-22.20%)
since 08/27/21
3-Month
48.33 +16.30%
on 07/19/21
76.22 -26.25%
on 06/30/21
-7.40 (-11.63%)
since 06/28/21
52-Week
45.01 +24.88%
on 09/29/20
151.80 -62.97%
on 12/09/20
+10.45 (+22.84%)
since 09/28/20

Most Recent Stories

More News
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots

/PRNewswire/ --   -  Using the same technology as their Covid-19 shot, scientists behind the and (NASDAQ:AZN) are getting closer to developing a , based on promising animal studies results. Based...

AZN : 57.63 (-1.86%)
BIOV.CN : 0.450 (-3.23%)
BVAXF : 0.3549 (-8.20%)
BNTX : 276.52 (-9.95%)
MRNA : 384.21 (-6.02%)
CVAC : 56.08 (-0.20%)
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots

VANCOUVER – USA News Group – Using the same technology as their Covid-19 shot, scientists ...

BVAXF : 0.3549 (-8.20%)
AZN : 57.63 (-1.86%)
BNTX : 276.52 (-9.95%)
MRNA : 384.21 (-6.02%)
CVAC : 56.08 (-0.20%)
BIOV.CN : 0.450 (-3.23%)
CureVac Streamlines European Network for mRNA Product Manufacturing

CureVac right-sizes manufacturing network to adapt to changes in vaccine peak demandsDemand reassessed for first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review with EMAContracts...

CVAC : 56.08 (-0.20%)
Glaxo (GSK), SK bioscience's COVID-19 Jab Enters Phase III Study

GlaxoSmithKline (GSK) and SK bioscience begin a phase III study on GBP510, the latter's COVID-19 vaccine candidate. The study will compare GBP510 against AstraZeneca's COVID-19 vaccine.

SNY : 47.90 (-0.46%)
AZN : 57.63 (-1.86%)
GSK : 38.05 (-1.17%)
CVAC : 56.08 (-0.20%)
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 31, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic...

CVAC : 56.08 (-0.20%)
CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

Findings in preclinical mouse models provide first direct proof of efficacy of HNF4A mRNA therapeutics in the treatment of liver fibrosis and cirrhosisFurther research aimed at optimizing mRNA therapeutic...

CVAC : 56.08 (-0.20%)
Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations

Regulatory and pipeline updates from Moderna (MRNA) and CureVac (CVAC) among others were in focus in the biotech industry over the past week.

GSK : 38.05 (-1.17%)
MRNA : 384.21 (-6.02%)
EXEL : 20.60 (-0.48%)
RIGL : 3.65 (-3.44%)
CVAC : 56.08 (-0.20%)
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update

CVAC : 56.08 (-0.20%)
Pre-Market Brief: Stocks Poised to Open Lower on Disappointing Chinese Data

Morning Markets Sep S&P 500 futures this morning are down -0.36% on concern the global economic rebound is faltering in the wake of weak Chinese economic data. Concern that the pandemic is worsening is...

TSLA : 777.56 (-1.74%)
CCL : 26.17 (-0.80%)
NCLH : 27.93 (-1.45%)
RCL : 91.97 (-0.48%)
DIDI : 7.98 (-3.16%)
JD : 75.42 (-1.32%)
PDD : 89.00 (-7.60%)
BABA : 152.39 (+1.47%)
BIDU : 154.02 (-1.86%)
TME : 7.10 (-1.66%)
SONO : 33.80 (-3.18%)
CVAC : 56.08 (-0.20%)
PCG : 9.74 (-2.31%)
ALB : 216.45 (-2.61%)
Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More

The biotech sector was in focus last week on the collaboration news from Alector (ALEC) and pipeline updates from CureVac (CVAC).

GSK : 38.05 (-1.17%)
PFE : 43.04 (-1.22%)
SPRO : 19.07 (-2.05%)
ALEC : 23.44 (-2.29%)
CVAC : 56.08 (-0.20%)
KTRA : 0.8670 (-1.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CureVac B.V. is a clinical-stage biopharmaceutical company. It engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102. CureVac B.V. is based in Germany.

See More

Key Turning Points

3rd Resistance Point 61.62
2nd Resistance Point 59.99
1st Resistance Point 58.09
Last Price 56.08
1st Support Level 54.56
2nd Support Level 52.93
3rd Support Level 51.03

See More

52-Week High 151.80
Fibonacci 61.8% 111.01
Fibonacci 50% 98.40
Fibonacci 38.2% 85.80
Last Price 56.08
52-Week Low 45.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar